Regulatory pharmacovigilance in the United Kingdom: Current principles and practice

Pharmacoepidemiology and Drug Safety

Volumn 5, Issue 6, 1996, Pages 363-375

  Waller, Patrick C ^a   Coulson, Rosalind A ^a   Wood, Susan M ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; CLOZAPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYPROTERONE ACETATE; HALOFANTRINE; KETOROLAC; KREON; MOXISYLYTE; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRIZYME; ORAL CONTRACEPTIVE AGENT; PANCRELIPASE; PANZYTRAT; PAROXETINE; QUINOLONE DERIVATIVE; REMOXIPRIDE; RIFABUTIN; TACROLIMUS; TAMOXIFEN; TIAPROFENIC ACID; TRAMADOL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; DRUG MONITORING; DRUG SAFETY; DRUG USE; HUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0030497852     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199611)5:6<363::AID-PDS249>3.0.CO;2-7     Document Type: Review

References (30)

1. Wood, S. M. Post-marketing surveillance: viewpoint from a regulatory authority. Drug Information Journal 1991; 25: 191-195.
2. Committee on Safety of Medicines/Medicines Control Agency. Pharmacovigilance. Current Problems in Pharmacovigilance 1993; 19: 1.
3. Rawlins, M. D. Spontaneous reporting of adverse drug reactions. Br. J. clin. Pharmacol. 1988; 26: 1-5 & 7-11.
4. Wood, S. M. and Coulson, R. A. Adverse Drug Reactions On-line Information Tracking (ADROIT). Pharmaceutical Medicine 1993; 7: 203-213.
5. Waller, P. C., Wood, S. M., Langman, M. J. S., Breckenridge, A. M. and Rawlins, M. D. Review of company post-marketing surveillance studies. Br. Med. J. 1992; 304: 1470-1472.
6. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry. Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM guidelines). Br. J. clin. Pharmacol. 1993; 38: 95-97.
7. Commission of the European Communities. Draft Notice to Applicants, Chapter V Brussels, 1994, pp. 74-97.
8. Rawson, N. S. B., Pearce, G. L. and Inman, W. H. W. Prescription-event monitoring: methodology and recent progress. J. Clin. Epidemiol. 1990; 43: 509-522.
9. Jick, H., Jick, S. S. and Derby, L. E. Validation of information recorded on General Practitioner based computerised data resource in the United Kingdom. Br. Med. J. 1991; 302: 766-768.
10. Wood, S. M. and Waller, P. C. Record linkage databases for pharmacovigilance: a UK perspective. In: Databases for Pharmacovigilance, Walker S. R. (Ed.), Centre for Medicines Research, 1996; 47-54.
11. McDonald, T. M. and McDevitt, D. G. The Tayside Medicines Monitoring Unit (MEMO). In: Pharmacoepidemiology, Strom, B. L. (Ed.), John Wiley, Chichester, 2nd edition, 1994, pp. 245-255.
12. Medicines Control Agency. Pharmacovigilance in the new European system. MAIL 1995; 87: 4-5.
13. Committee for Proprietary Medicinal Products. Procedures for competent authorities on the undertaking of pharmacovigilance activities. CPMP 175/95, 1995.
14. Wood, S. Handling of drug safety alerts in the European Community. Pharmacoepidemiology and Drug Safety 1992; 1: 139-142.
15. Committee for Proprietary Medicinal Products. Note for Guidance on Rapid Alert Systems (RAS) in Pharmacovigilance. CPMP/PhVWP/005/6, 1996.
16. Bero, L. and Rennie, D. The Cochrane Collaboration - preparing, maintaining and disseminating systematic reviews of the effects of healthcare. Journal of the American Medical Association 1995; 274: 1935-1938.
17. Medicines Control Agency. The Patient Pack Initiative. MAIL (special edition April, 1995).
18. Medicines Control Agency. Guidance for the Pharmaceutical Industry on the Labelling and Leaflet Regulations. London, 1993.
19. Committee on Safety of Medicines/Medicines Control Agency. Relative safety of oral non-aspirin NSAIDs. Current Problems in Pharmacovigilance 1994; 20: 9-11.
20. Committee on Safety of Medicines/Medicines Control Agency. Myocarditis with antipsychotics: recent cases with clozapine. Current Problems in Pharmacovigilance 1993; 19: 9-10.
21. Committee on Safety of Medicines/Medicines Control Agency. Severe cystitis with tiaprofenic acid. Current Problems in Pharmacovigilance 1994; 20: 11.
22. Committee on Safety of Medicines/Medicines Control Agency. Editorial board for Current Problems. Current Problems in Pharmacovigilance 1993; 19: 4.
23. Committee on Safety of Medicines/Medicines Control Agency. Severe chickenpox associated with systemic corticosteroids. Current Problems in Pharmacovigilance 1994; 20: 1-2.
24. Committee on Safety of Medicines/Medicines Control Agency. Reye's syndrome and aspirin in children. Current Problems in Pharmacovigilance 1993; 19: 4.
25. Committee on Safety of Medicines/Medicines Control Agency. Neural tube defects associated with sodium valproate and carbamazepine - need for counselling and screening. Current Problems in Pharmacovigilance 1993; 19: 8.
26. Committee on Safety of Medicines/Medicines Control Agency. Drug-induced neutropenia and agranulocytosis. Current Problems in Pharmacovigilance 1993; 19: 9.
27. Medicines Control Agency. AEGIS update. MAIL 1995; 87: 7.
28. Moore, N., Montero, D., Coulson, R. et al. Communication in pharmacovigilance. Pharmacoepidemiology and Drug Safety 994; 3: 151-155.
29. Mitchard, M. and Wood, L. Regulatory communications. European Pharmaceutical Law Notebooks 1996; II: 139-155.
30. Wood, L. on behalf of the MEDDRA Working Party. The Medical Dictionary for Drug Regulatory Affairs. Pharmacoepidemiology and Drug Safety 1994; 3: 7-13.